Pain Therapeutics

Mylan Launches Generic Maxalt MLT Tablets

The pharmaceutical firm has received FDA approval for its migraine treatment.

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base). These products are the generic versions of Merck's Maxalt MLT® Tablets and Maxalt® Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults.

Your rating: None Average: 4.5 (2 votes)

FDA Approves Janssen’s NUCYNTA ER Pain Management Tablets

The extended-release oral tablets are intended for managing neuropathic pain associated with diabetes.

Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.

Your rating: None Average: 4 (1 vote)

Midlothian Labs Distributes Generic Oxycodone Capsules

The company has begun distributing a generic version of Oxycodone HCl 5 mg capsules.

The U.S. Food and Drug Administration approved the abbreviated new drug application July 26. This new AB-rated product is the first approved generic for the Reference Listed Drug (RLD) Oxycodone HCl 5 mg capsules manufactured by Lehigh Valley Technologies Inc.

Your rating: None Average: 5 (2 votes)

Lilly Releases Study on Back Pain Treatment in Postmenopausal Women

In the study, the company's FORTEO injection showed positive results in managing patients' pain.

Eli Lilly and Co. today announced data from a Phase III trial comparing the effects of FORTEO (teriparatide [rDNA origin] injection) and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures.

No votes yet

AcelRx Pharmaceuticals Receives U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms

The two new patents cover the company's family of sufentanil NanoTab pain products.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S.

No votes yet

Pain Therapeutics Lands Patents for Extended-release Oxycodone Capsules

The patents cover the company's REMOXY extended-release oxycodone capsules.

Pain Therapeutics Inc. a biopharmaceutical company, today announced the issuance of four patents by the U.S. Patent and Trademark Office covering REMOXY (oxycodone) Extended-Release Capsules CII. These patents are the result of joint inventive work by scientists from both Pain Therapeutics and Durect Corporation. The four issued patents are licensed exclusively to Pain Therapeutics in the United States and international markets with regards to four opioid drugs.

No votes yet
Syndicate content